Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma

Trial Profile

Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs Ibrutinib (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Acronyms iLOC
  • Most Recent Events

    • 06 Dec 2016 Interim results (n=18) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 06 Sep 2016 Status changed from recruiting to active, no longer recruiting.
    • 22 Feb 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top